An update on the clinical use of methadone for cancer pain

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain. Methadone has a number of unique characteristics including excellent oral and rectal absorption, no known active metabolites, high potency, low cost, and longer administration intervals, as well as an incomplete cross-tolerance with respect to other mu-opioid receptor agonist drugs. For these reasons, methadone has the potential of playing a major role in the treatment of cancer pain. However, its use is limited by the remarkably long and unpredictable half-life, large inter-individual variations in pharmacokinetics, the potential for delayed toxicity, and above all by the limited knowledge of correct administration intervals and the equianalgesic ratio with other opioids when administered chronically. Recent findings suggest that standard equianalgesic tables are unreliable for methadone titration in patients tolerant to high doses of opioid agonists and that switchovers should take place slowly and should be personalized. Future research has to better define the variation in both bioavailability and elimination of methadone in different patient populations, the interaction between methadone and the most commonly used drugs in cancer patients, the type and activity of potential methadone metabolites, and the equianalgesic doses between methadone and the most commonly used opioids.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalPain
Volume70
Issue number2-3
DOIs
Publication statusPublished - 1997

Fingerprint

Methadone
Opioid Analgesics
Pharmaceutical Preparations
Cancer Pain
mu Opioid Receptor
Biological Availability
Half-Life
Pharmacokinetics
Costs and Cost Analysis
Population

Keywords

  • cancer pain
  • equianalgesia
  • methadone
  • oral and rectal route

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

An update on the clinical use of methadone for cancer pain. / Ripamonti, Carla; Zecca, Ernesto; Bruera, Eduardo.

In: Pain, Vol. 70, No. 2-3, 1997, p. 109-115.

Research output: Contribution to journalArticle

Ripamonti, Carla ; Zecca, Ernesto ; Bruera, Eduardo. / An update on the clinical use of methadone for cancer pain. In: Pain. 1997 ; Vol. 70, No. 2-3. pp. 109-115.
@article{2ab8aa1a88cc415c843256640adef8b0,
title = "An update on the clinical use of methadone for cancer pain",
abstract = "Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain. Methadone has a number of unique characteristics including excellent oral and rectal absorption, no known active metabolites, high potency, low cost, and longer administration intervals, as well as an incomplete cross-tolerance with respect to other mu-opioid receptor agonist drugs. For these reasons, methadone has the potential of playing a major role in the treatment of cancer pain. However, its use is limited by the remarkably long and unpredictable half-life, large inter-individual variations in pharmacokinetics, the potential for delayed toxicity, and above all by the limited knowledge of correct administration intervals and the equianalgesic ratio with other opioids when administered chronically. Recent findings suggest that standard equianalgesic tables are unreliable for methadone titration in patients tolerant to high doses of opioid agonists and that switchovers should take place slowly and should be personalized. Future research has to better define the variation in both bioavailability and elimination of methadone in different patient populations, the interaction between methadone and the most commonly used drugs in cancer patients, the type and activity of potential methadone metabolites, and the equianalgesic doses between methadone and the most commonly used opioids.",
keywords = "cancer pain, equianalgesia, methadone, oral and rectal route",
author = "Carla Ripamonti and Ernesto Zecca and Eduardo Bruera",
year = "1997",
doi = "10.1016/S0304-3959(96)03286-1",
language = "English",
volume = "70",
pages = "109--115",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - An update on the clinical use of methadone for cancer pain

AU - Ripamonti, Carla

AU - Zecca, Ernesto

AU - Bruera, Eduardo

PY - 1997

Y1 - 1997

N2 - Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain. Methadone has a number of unique characteristics including excellent oral and rectal absorption, no known active metabolites, high potency, low cost, and longer administration intervals, as well as an incomplete cross-tolerance with respect to other mu-opioid receptor agonist drugs. For these reasons, methadone has the potential of playing a major role in the treatment of cancer pain. However, its use is limited by the remarkably long and unpredictable half-life, large inter-individual variations in pharmacokinetics, the potential for delayed toxicity, and above all by the limited knowledge of correct administration intervals and the equianalgesic ratio with other opioids when administered chronically. Recent findings suggest that standard equianalgesic tables are unreliable for methadone titration in patients tolerant to high doses of opioid agonists and that switchovers should take place slowly and should be personalized. Future research has to better define the variation in both bioavailability and elimination of methadone in different patient populations, the interaction between methadone and the most commonly used drugs in cancer patients, the type and activity of potential methadone metabolites, and the equianalgesic doses between methadone and the most commonly used opioids.

AB - Methadone is a synthetic opioid agonist considered a second choice drug in the management of cancer pain. Methadone has a number of unique characteristics including excellent oral and rectal absorption, no known active metabolites, high potency, low cost, and longer administration intervals, as well as an incomplete cross-tolerance with respect to other mu-opioid receptor agonist drugs. For these reasons, methadone has the potential of playing a major role in the treatment of cancer pain. However, its use is limited by the remarkably long and unpredictable half-life, large inter-individual variations in pharmacokinetics, the potential for delayed toxicity, and above all by the limited knowledge of correct administration intervals and the equianalgesic ratio with other opioids when administered chronically. Recent findings suggest that standard equianalgesic tables are unreliable for methadone titration in patients tolerant to high doses of opioid agonists and that switchovers should take place slowly and should be personalized. Future research has to better define the variation in both bioavailability and elimination of methadone in different patient populations, the interaction between methadone and the most commonly used drugs in cancer patients, the type and activity of potential methadone metabolites, and the equianalgesic doses between methadone and the most commonly used opioids.

KW - cancer pain

KW - equianalgesia

KW - methadone

KW - oral and rectal route

UR - http://www.scopus.com/inward/record.url?scp=0030928512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030928512&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(96)03286-1

DO - 10.1016/S0304-3959(96)03286-1

M3 - Article

VL - 70

SP - 109

EP - 115

JO - Pain

JF - Pain

SN - 0304-3959

IS - 2-3

ER -